-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The current conventional imaging methods, including enhanced CT, MRI, and 99mTc-methylene bisphosphonate (MDP) bone imaging, are not ideal methods for detecting metastatic sites of metastatic prostate cancer (PCa) in different states.
OSPREY is a prospective trial designed to determine the diagnostic performance of 18F-DCFPyL-PET/CT in detecting metastatic prostate cancer .
It intended to identify 18F-DCFPyL-PET / CT in the detection of metastatic prostate cancer site diagnostic performance aimed at determining 18F-DCFPyL-PET / CT in the detection of metastatic prostate cancer site diagnosis performance diagnostic
Two groups of patients underwent 18F-DCFPyL-PET/CT examination: Group A included high-risk PCa patients who underwent radical prostatectomy and pelvic lymphadenectomy; Group B included pre-PCa patients who were suspected of recurrence/metastasis by routine imaging examination.
A total of 385 patients were included.
In group A (252 evaluable subjects), the median specificity of 18F-DCFPyL-PET/CT in detecting pelvic lymph node metastasis was 97.
In group B (n=93, median PSA was 11.
In group B (n=93, median PSA was 11.
The specificity of PSMA-targeted PET/CT to detect metastatic prostate cancer reached the predetermined primary endpoint, but the sensitivity did not.
Original source:
Pienta Kenneth J, Gorin Michael A, Rowe Steven P et al.
org/10.
1097/JU.
0000000000001698" target="_blank" rel="noopener">A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate-Specific Membrane Antigen PET / CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY) in this message